Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CWBR CohBar	$0.41	$0.41	$0.00 ▼ $1.01	$1.19M	1.39	4,364 shs	N/A
DRMA Dermata Therapeutics	$6.11 -0.8%	$6.78	$5.74 ▼ $24.90	$3.93M	0.56	25,526 shs	31,705 shs
INM InMed Pharmaceuticals	$2.21 -1.8%	$2.73	$1.72 ▼ $15.70	$4.50M	0.29	77,520 shs	65,436 shs
MTNB Matinas Biopharma	$1.48 -7.5%	$0.95	$0.47 ▼ $8.39	$7.53M	1.32	298,598 shs	398,406 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CWBR CohBar	0.00%	0.00%	0.00%	0.00%	+2.24%
DRMA Dermata Therapeutics	-2.07%	-12.75%	-13.24%	-20.97%	-74.96%
INM InMed Pharmaceuticals	+0.45%	-5.06%	-18.18%	-14.12%	-19.64%
MTNB Matinas Biopharma	+41.33%	+66.88%	+55.05%	+144.45%	+759.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CWBR CohBar	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	2.156 of 5 stars	3.5	3.0	0.0	0.0	1.4	0.8	0.6
INM InMed Pharmaceuticals	0.1015 of 5 stars	0.0	2.0	0.0	0.0	0.6	0.0	0.6
MTNB Matinas Biopharma	0.5833 of 5 stars	0.0	5.0	0.0	0.0	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CWBR CohBar	0.00	N/A	N/A	N/A
DRMA Dermata Therapeutics	3.00	Buy	$30.00	391.00% Upside
INM InMed Pharmaceuticals	0.00	N/A	N/A	N/A
MTNB Matinas Biopharma	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest CWBR, INM, MTNB, and DRMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/21/2025	DRMA Dermata Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $30.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CWBR CohBar	N/A	N/A	N/A	N/A	$5.27 per share	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	$6.20 per share	N/A
INM InMed Pharmaceuticals	$4.60M	0.96	N/A	N/A	$20.64 per share	0.11
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	$4.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CWBR CohBar	-$12.18M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	-$12.29M	-$16.41	N/A	∞	N/A	N/A	-270.81%	-179.96%	8/13/2025 (Estimated)
INM InMed Pharmaceuticals	-$7.68M	-$12.09	N/A	∞	N/A	-168.87%	-107.93%	-82.97%	9/26/2025 (Estimated)
MTNB Matinas Biopharma	-$22.94M	-$3.86	N/A	∞	N/A	N/A	-123.06%	-94.28%	N/A

Latest CWBR, INM, MTNB, and DRMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	DRMA Dermata Therapeutics	-$4.50	-$4.50	N/A	-$0.45	N/A	N/A
5/12/2025	Q3 2025	INM InMed Pharmaceuticals	N/A	-$1.94	N/A	-$1.94	N/A	$1.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CWBR CohBar	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A
INM InMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CWBR CohBar	N/A	N/A	N/A
DRMA Dermata Therapeutics	N/A	3.70	3.70
INM InMed Pharmaceuticals	0.06	3.49	3.04
MTNB Matinas Biopharma	N/A	5.53	5.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CWBR CohBar	2.47%
DRMA Dermata Therapeutics	8.67%
INM InMed Pharmaceuticals	20.12%
MTNB Matinas Biopharma	11.77%

Insider Ownership

Company	Insider Ownership
CWBR CohBar	6.51%
DRMA Dermata Therapeutics	18.50%
INM InMed Pharmaceuticals	1.43%
MTNB Matinas Biopharma	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CWBR CohBar	10	2.91 million	N/A	Not Optionable
DRMA Dermata Therapeutics	8	640,000	520,000	Not Optionable
INM InMed Pharmaceuticals	10	2.00 million	1.97 million	Not Optionable
MTNB Matinas Biopharma	30	5.09 million	4.60 million	N/A

CWBR, INM, MTNB, and DRMA Headlines

Recent News About These Companies

MTNB Matinas BioPharma Holdings, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Matinas BioPharma Holdings, Inc. (MTNB) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Kalkine Matinas BioPharma Surges Amid NYSE Composite Market Momentum

June 7, 2025 | kalkinemedia.comK

Matinas BioPharma amends bylaws, updates on officer agreements

May 4, 2025 | investing.com

Matinas BioPharma files to sell 16.9M shares of common stock for holders

April 24, 2025 | markets.businessinsider.com

Matinas BioPharma secures shareholder nods on key proposals

April 6, 2025 | investing.com

Matinas BioPharma announces board chairman’s departure

March 16, 2025 | investing.com

Matinas BioPharma appoints Murphy, Neugeboren to board of directors

March 11, 2025 | markets.businessinsider.com

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

March 11, 2025 | finance.yahoo.com

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

February 13, 2025 | globenewswire.com

Matinas BioPharma announces board member retirement

February 11, 2025 | msn.com

Matinas BioPharma Appoints Evelyn D’An as Independent Director and Audit Committee Chair

February 9, 2025 | nasdaq.com

Matinas BioPharma appoints Evelyn D’An to board of directors

February 7, 2025 | markets.businessinsider.com

Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

February 7, 2025 | finance.yahoo.com

Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

February 7, 2025 | globenewswire.com

Matinas BioPharma announces board member resignation

January 25, 2025 | msn.com

111 Equity Group increases stake in Matinas BioPharma

January 24, 2025 | markets.businessinsider.com

111 Equity ups stake in Matinas Biopharma Holdings

January 24, 2025 | msn.com

111 Equity Group increases stake in Matinas Biopharma Holdings, Inc.

January 24, 2025 | finance.yahoo.com

What Factors Have Led to Matinas BioPharma Holdings Inc (MTNB) Stock Trading -96.74% Below Its 52-Week High?

January 15, 2025 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CWBR, INM, MTNB, and DRMA Company Descriptions

CohBar NASDAQ:CWBR

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

Dermata Therapeutics NASDAQ:DRMA

$6.11 -0.05 (-0.81%)

As of 04:00 PM Eastern

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

InMed Pharmaceuticals NASDAQ:INM

$2.21 -0.04 (-1.78%)

Closing price 04:00 PM Eastern

Extended Trading

$2.18 -0.03 (-1.31%)

As of 07:56 PM Eastern

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Matinas Biopharma NYSE:MTNB

$1.48 -0.12 (-7.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.49 +0.01 (+0.68%)

As of 07:54 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time